(VRNA) Verona Pharma - Ratings and Ratios
Inhaled Bronchodilator/Anti-Inflammatory
VRNA EPS (Earnings per Share)
VRNA Revenue
Description: VRNA Verona Pharma
Verona Pharma PLC ADR (NASDAQ:VRNA) is a biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases with unmet medical needs, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Their lead product, Ohtuvayre, is a dual inhibitor that combines bronchodilator and anti-inflammatory effects.
From a financial perspective, Verona Pharma has a market capitalization of approximately $8.9 billion USD, indicating a significant presence in the pharmaceutical industry. The companys forward Price-to-Earnings (P/E) ratio is around 476, suggesting high growth expectations. However, the Return on Equity (RoE) is -89.89%, indicating that the company is currently not profitable.
To further evaluate VRNAs potential, we can examine key performance indicators (KPIs) such as revenue growth, research and development (R&D) expenses, and cash reserves. A high R&D expenditure as a percentage of revenue may indicate a strong commitment to innovation, but it also increases the burn rate. Monitoring the companys cash runway and funding plans will be crucial in assessing its ability to bring new therapies to market.
From a technical analysis perspective, VRNAs stock price has shown significant support levels between $54 and $73.7. The current price is near its 52-week high, indicating strong momentum. However, the high ATR (Average True Range) percentage suggests potential volatility, and investors should be cautious of potential price swings.
To make an informed investment decision, its essential to weigh the potential benefits of VRNAs pipeline and commercial products against the risks associated with the companys financials and market dynamics. A thorough analysis of the companys competitive landscape, regulatory environment, and future growth prospects is necessary to determine the stocks potential for long-term success.
VRNA Stock Overview
| Market Cap in USD | 9,042m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2017-04-27 |
VRNA Stock Ratings
| Growth Rating | 96.4% |
| Fundamental | 41.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 207% |
| Analyst Rating | 4.70 of 5 |
VRNA Dividends
Currently no dividends paidVRNA Growth Ratios
| Growth Correlation 3m | 96.7% |
| Growth Correlation 12m | 98% |
| Growth Correlation 5y | 84.9% |
| CAGR 5y | 121.79% |
| CAGR/Max DD 3y | 2.17 |
| CAGR/Mean DD 3y | 8.42 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | 0.15 |
| Beta | 0.779 |
| Volatility | 26.48% |
| Current Volume | 2297.9k |
| Average Volume 20d | 1128k |
| Stop Loss | 103.1 (-3%) |
| Signal | 0.76 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-81.2m TTM) > 0 and > 6% of Revenue (6% = 13.3m TTM) |
| FCFTA -0.21 (>2.0%) and ΔFCFTA -9.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 224.5% (prev 39.1k%; Δ -38.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.13 (>3.0%) and CFO -72.5m > Net Income -81.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (90.9m) change vs 12m ago 12.19% (target <= -2.0% for YES) |
| Gross Margin 95.15% (prev 4.57%; Δ 90.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 44.03% (prev 0.22%; Δ 43.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.01 (EBITDA TTM -36.6m / Interest Expense TTM 37.2m) >= 6 (WARN >= 3) |
Altman Z'' 0.09
| (A) 0.87 = (Total Current Assets 548.9m - Total Current Liabilities 51.2m) / Total Assets 572.9m |
| (B) -0.99 = Retained Earnings (Balance) -567.1m / Total Assets 572.9m |
| (C) -0.07 = EBIT TTM -37.7m / Avg Total Assets 503.5m |
| (D) -1.79 = Book Value of Equity -526.7m / Total Liabilities 294.6m |
| Total Rating: 0.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.47
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -1.39% = -0.69 |
| 3. FCF Margin -55.39% = -7.50 |
| 4. Debt/Equity 0.87 = 2.13 |
| 5. Debt/Ebitda -6.65 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -38.66% = -2.50 |
| 8. Rev. Trend 82.84% = 6.21 |
| 9. EPS Trend -3.65% = -0.18 |
What is the price of VRNA shares?
Over the past week, the price has changed by -0.08%, over one month by +0.47%, over three months by +14.38% and over the past year by +264.13%.
Is Verona Pharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRNA is around 136.35 USD . This means that VRNA is currently undervalued and has a potential upside of +28.28% (Margin of Safety).
Is VRNA a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VRNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 106.2 | -0.1% |
| Analysts Target Price | 106.2 | -0.1% |
| ValueRay Target Price | 152.6 | 43.5% |
Last update: 2025-09-13 05:05
VRNA Fundamental Data Overview
CCE Cash And Equivalents = 438.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 34.965
P/S = 40.7887
P/B = 33.0724
Beta = 0.135
Revenue TTM = 221.7m USD
EBIT TTM = -37.7m USD
EBITDA TTM = -36.6m USD
Long Term Debt = 242.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 243.4m USD (Calculated: Short Term 1.01m + Long Term 242.4m)
Net Debt = -193.6m USD (from netDebt column, last quarter)
Enterprise Value = 8.85b USD (9.04b + Debt 243.4m - CCE 438.0m)
Interest Coverage Ratio = -1.01 (Ebit TTM -37.7m / Interest Expense TTM 37.2m)
FCF Yield = -1.39% (FCF TTM -122.8m / Enterprise Value 8.85b)
FCF Margin = -55.39% (FCF TTM -122.8m / Revenue TTM 221.7m)
Net Margin = -36.62% (Net Income TTM -81.2m / Revenue TTM 221.7m)
Gross Margin = 95.15% ((Revenue TTM 221.7m - Cost of Revenue TTM 10.7m) / Revenue TTM)
Tobins Q-Ratio = -16.80 (set to none) (Enterprise Value 8.85b / Book Value Of Equity -526.7m)
Interest Expense / Debt = 2.80% (Interest Expense 6.82m / Debt 243.4m)
Taxrate = -0.33% (set to none) (-39.0k / 11.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 10.71 (Total Current Assets 548.9m / Total Current Liabilities 51.2m)
Debt / Equity = 0.87 (Debt 243.4m / last Quarter total Stockholder Equity 278.3m)
Debt / EBITDA = -6.65 (Net Debt -193.6m / EBITDA -36.6m)
Debt / FCF = -1.98 (Debt 243.4m / FCF TTM -122.8m)
Total Stockholder Equity = 210.0m (last 4 quarters mean)
RoA = -14.17% (Net Income -81.2m, Total Assets 572.9m )
RoE = -38.66% (Net Income TTM -81.2m / Total Stockholder Equity 210.0m)
RoCE = -8.34% (Ebit -37.7m / (Equity 210.0m + L.T.Debt 242.4m))
RoIC = unknown (NOPAT none, Invested Capital 391.1m, Ebit -37.7m)
WACC = unknown (E(9.04b)/V(9.29b) * Re(8.89%)) + (D(243.4m)/V(9.29b) * Rd(2.80%) * (1-Tc(none)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.67%
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -122.8m)
EPS Correlation: -3.65 | EPS CAGR: 11.15% | SUE: -0.15 | # QB: 0
Revenue Correlation: 82.84 | Revenue CAGR: 2031 % | SUE: N/A | # QB: None
Additional Sources for VRNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle